Cftr Trikafta denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Trikafta as Not Medically Necessary — and How to Appeal

A medical-necessity denial for Trikafta (elexacaftor/tezacaftor/ivacaftor) from UnitedHealthcare (UHC) means the plan's reviewers determined that the submitted documentation did not demonstrate that the medication meets UHC's clinical criteria for coverage. This is not a finding that the drug is ineffective — it is a finding that the documentation package was insufficient. That is a correctable problem.

## Why This Denial Happens

UHC maintains a published medical policy for CFTR modulators that sets out specific clinical criteria — including diagnosis confirmation, mutation type, age range, and sometimes prior-treatment requirements. Medical-necessity denials occur when the prior-authorization submission is missing one or more of those criteria, when the clinical notes do not explicitly document the required findings, or when the reviewing clinician applied the criteria inconsistently. Because these are documentation-driven denials, appeals that directly map chart evidence to each policy criterion succeed at a meaningful rate.

## Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer plans) or state law (individual/fully-insured plans), you have the right to a full internal appeal reviewed by a clinical peer — not the same reviewer who issued the original denial. File within the deadline on the denial letter, typically 180 days.
• External review (ACA §2719): If the internal appeal is denied, you may request an independent external review within approximately four months of the final internal denial. The external reviewer applies evidence-based medical standards independent of UHC's formulary preferences.
• Expedited review: If treatment delay would seriously jeopardize health or ability to regain maximum function, request expedited review (72-hour turnaround required).

## Documentation to Gather

1. Diagnosis confirmation — pulmonologist or CF specialist chart notes confirming the CF diagnosis and the specific CFTR mutation(s) identified on genetic testing. 2. Mutation-indication match — documentation showing the mutation type falls within the FDA-approved prescribing label for Trikafta. 3. Clinical severity and functional status — recent lung function data, pulmonary exacerbation history, nutritional status, and any hospitalizations — drawn directly from the chart. 4. Prescriber medical-necessity letter — a detailed letter from the CF specialist explaining why Trikafta is medically necessary for this patient, referencing UHC's stated criteria individually and the Cystic Fibrosis Foundation care guidelines. 5. Prior-treatment history — if UHC's policy includes prior-therapy requirements, document all prior CF treatments with start/stop dates and clinical outcomes.

## Criteria-Mapping Structure

Obtain UHC's current published coverage/medical policy for Trikafta and the FDA prescribing label. Build a criterion-by-criterion response table:

| UHC Coverage Criterion | Satisfying Evidence in the Chart or Letter | |---|---| | Each individual criterion listed in UHC's policy | Specific chart entry, date, test result, or prescriber statement | | FDA-label indication | Documented mutation type | | Clinical necessity standard | Severity data + CFF guideline reference |

Submitting this table as the appeal letter body — rather than a narrative alone — substantially increases the chance of reversal because it removes the reviewer's need to interpret or search for the evidence.